Table 1.

Design and results of studies with injectable iron treatment in patients with heart failure

Study	Patients	Design	Anemia/ ID	Treatment	Follow-up	Outcomes
Bolger et al.39 (2006)	16	Open	Anemia	Iron sucrose max 1000 mg	92 days	Corrected anemia and improved NYHA class, MLWHF score and 6MWD
Toblli et al.40 (2007)	40	Randomized, double-blind	Anemia and ID	Iron sucrose 1000 mg	6 months	Corrected anemia and reduced NT-pro BNP, CRP, improved NYHA class, MLWHF score and 6MWD
Usmanov et al.41 (2008)	32	Open	Anemia with ID	Iron sucrose 3200 mg	26 weeks	Corrected anemia and improved cardiac remodeling and NYHA class
Okonko et al.42 (2008) FERRIC-HF study	35	Randomized	Anemia and ID	Iron sucrose 200 mg/week for 16 weeks	18 weeks	Improved peak VO2, NYHA class
Anker et al.43 (2009) FAIR-HF study	459	Randomized, double-blind	Iron deficiency	Ferric carboxymaltose 200 mg/week until corrected	24 weeks	Improved Patient Global Assessment, NYHA class, 6MWD, KCCQ score
Gaber et al.44 (2012)	40	Open	Iron deficiency	Iron dextran 200 mg/week until correction	12 weeks	Improved myocardial function systolic and diastolic function determined by tissue Doppler and strain rate
Ponikowski et al.45(2015) CONFIRM_HF study	304	Randomized, double-blind	Iron deficiency	Ferric carboxymaltose 500-2500 mg	52 weeks	Improved 6MWD, NYHA class, KCCQ score, decreased risk of hospitalization

HF - heart failure; ID - iron deficiency; MLWHF - Minnesota living with heart failure; 6MWD - 6-minute walking test; KCCQ - Kansas City Cardiomyopathy Questionnaire; NYHA - New York Heart Association